Cisplatin application in pregnancy: first in vivo analysis of 7 patients.

Cervical cancer in pregnancy is an oncologic challenge. Empirical cisplatin is recommended to prevent cancer progression until fetal maturity. Seven patients with cervical cancer in the second trimester decided to delay delivery together with neoadjuvant chemotherapy. After 2-4 cycles, caesarean section and radical hysterectomy were performed above 32 weeks of gestation. Synchronous samples from maternal blood, umbilical cord blood and amniotic fluid were taken. All patients delivered healthy babies. Cisplatin concentrations in umbilical cord and amniotic fluid were 31-65 and 13-42% of the maternal blood, respectively. This is the first series on in vivo cisplatin concentration in the fetomaternal compartment.